Syndromes predisposing to pediatric central nervous system tumors: Lessons learned and new promises

Current Neurology and Neuroscience Reports

Volumn 12, Issue 2, 2012, Pages 153-164

  Villani, Anita ^a   Malkin, David ^a   Tabori, Uri ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Brain tumor; Cancer predisposition; Central nervous system tumors; Child

Indexed keywords

BEVACIZUMAB; CYCLOPAMINE; ERLOTINIB; EVEROLIMUS; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEUROFIBROMIN; RAPAMYCIN; SONIC HEDGEHOG PROTEIN; TIPIFARNIB;

ACOUSTIC NEURINOMA; ARTICLE; BASAL CELL NEVUS SYNDROME; BRAIN TUMOR POLYPOSIS SYNDROME 1; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FANC N GENE; FANCONI ANEMIA; GENE MUTATION; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; GLIOMA; HUMAN; MEDULLOBLASTOMA; MLH1 GENE; MSH2 GENE; MSH6 GENE; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; PALB2 GENE; PHENOTYPE; PMS2 GENE; PTCH GENE; RHABDOID TUMOR PREDISPOSITION SYNDROME; SMARCB1 GENE; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SYNDROME; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; TURCOT SYNDROME;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PEDIATRICS; SYNDROME;

EID: 84861232260     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0244-5     Document Type: Article

References (95)

1. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol. 2010;28:1995-2001.
2. Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Canc. 2011;56:7-15.
3. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124-33.
4. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis 1988;1:172-8.
5. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181-6.
6. McGillicuddy LT, Fromm JA, Hollstein PE, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009;16:44-54.
7. Banerjee S, Crouse NR, Emnett RJ, et al. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci USA. 2011.
8. Yunoue S, Tokuo H, Fukunaga K, et al. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J Biol Chem. 2003;278:26958-69. (Pubitemid 36876849)
9. Warrington NM, Gianino SM, Jackson E, et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 2010;70:5717-27.
10. Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclaseactivating polypeptide-mediated signaling in astrocytes. J Neurosci. 2003;23:8949-54. (Pubitemid 37210908)
11. Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:4572-8. (Pubitemid 46594029)
12. Opocher E, Kremer LC, Da Dalt L, et al. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer. 2006;42:1807-16. (Pubitemid 44149098)
13. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86:747-54. (Pubitemid 27187674)
14. Grill J, Laithier V, Rodriguez D, et al. When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr. 2000;159:692-6. (Pubitemid 30658557)
15. Gutmann DH, Listernick R, Ferner RE. Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1. Eye (Lond). 2011;25:818. author reply 818-819.
16. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61:189-98. (Pubitemid 46557343)
17. Huttner AJ, Kieran MW, Yao X, et al. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Canc. 2010;54:890-6.
18. Rosenfeld A, Listernick R, Charrow J, Goldman S. Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst. 2010;26:663-7.
19. Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006;24:507-16. (Pubitemid 46630471)
20. Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer. 1991;64:959-61.
21. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841-51. (Pubitemid 26192135)
22. Cohen Jr MM. The hedgehog signaling network. Am J Med Genet A. 2003;123A:5-28. (Pubitemid 37309353)
23. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31:306-10.
24. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308. (Pubitemid 27154674)
25. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6:530-9. (Pubitemid 39576548)
26. Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer. 2003;98:618-24. (Pubitemid 36886004)
27. Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol. 2009;24:1526-35.
28. Choudry Q, Patel HC, Gurusinghe NT, Evans DG. Radiationinduced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Childs Nerv Syst. 2007;23:133-6. (Pubitemid 46138500)
29. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978-86. (Pubitemid 40349500)
30. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406:1005-9.
31. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130-40.
32. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173-8.
33. Northcott PA, Korshunov A,Witt H, et al.Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2010;29:1408-14.
34. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125-7.
35. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13:624-8. (Pubitemid 29035481)
36. Sancak O, Nellist M, Goedbloed M, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13:731-41. (Pubitemid 40846845)
37. Weiner DM, Ewalt DH, Roach ES, Hensle TW. The tuberous sclerosis complex: a comprehensive review. J Am Coll Surg. 1998;187:548-61. (Pubitemid 28506864)
38. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345-56.
39. Torres OA, Roach ES, Delgado MR, et al. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol. 1998;13:173-7. (Pubitemid 28222064)
40. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490-8. (Pubitemid 43358069)
41. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-11.
42. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071-81.
43. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008;358:200-3.
44. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34. (Pubitemid 37328884)
45. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162-4. (Pubitemid 46184345)
46. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2007;44:1-9. (Pubitemid 46142832)
47. Neveling K, Endt D, Hoehn H, Schindler D. Genotype-phenotype correlations in Fanconi anemia. Mutat Res. 2009;668:73-91.
48. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20:4621-8. (Pubitemid 32762434)
49. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-8. (Pubitemid 120031831)
50. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27:e108-109. author reply e110.
51. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28:1345-50.
52. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346:420-7. (Pubitemid 34437697)
53. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12:559-67.
54. Turcot J, Despres JP. St Pierre F: Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum. 1959;2:465-8.
55. Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol. 1997;15:2744-58. (Pubitemid 27289909)
56. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet. 2008;124:105-22.
57. Kruger S, Kinzel M, Walldorf C, et al. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet. 2008;16:62-72. (Pubitemid 350269240)
58. Wang Q, Montmain G, Ruano E, et al. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet. 2003;112:117-23. (Pubitemid 36869093)
59. Durno CA, Holter S, Sherman PM, Gallinger S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol. 2010;105:2449-56.
60. NCCN Colorectal Cancer Screening Panel: NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening V2.2011.
61. Dumo C, Hawkins C, Aronson M, et al. Distinctive clinical, genetic and cancer features of children with mismatch repair cancer susceptibility and RAS/MAPK syndromes [abstract 2010- A-294-ISPNO]. Presented at the 14th International Symposium on Pediatric Neuro-oncology (ISPNO). Vienna, Austria; June 20-23, 2010.
62. Gottschling S, Reinhard H, Pagenstecher C, et al. Hypothesis: Possible role of retinoic acid therapy in patients with biallelic mismatch repair gene defects. Eur J Pediatr. 2008;167:225-9.
63. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044-58.
64. Ikeda J, Sawamura Y, van Meir EG. Pineoblastoma presenting in familial adenomatous polyposis (FAP): random association, FAP variant or Turcot syndrome? Br J Neurosurg. 1998;12:576-8. (Pubitemid 28566958)
65. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995;332:839-47.
66. Benchabane H, Ahmed Y. The adenomatous polyposis coli tumor suppressor and Wnt signaling in the regulation of apoptosis. Adv Exp Med Biol. 2009;656:75-84.
67. Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer. 2007;109:761-6. (Pubitemid 46233238)
68. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813-20. (Pubitemid 44464063)
69. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373:1974-86.
70. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature. 1993;363:515-21. (Pubitemid 23186636)
71. Wong HK, Lahdenranta J, Kamoun WS, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010;70:3483-93.
72. Baser ME, Friedman JM, Joe H, et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med. 2011;13:576-81.
73. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841-6. (Pubitemid 23035205)
74. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19:5-12. (Pubitemid 40824366)
75. Twomey JG, Bove C, Cassidy D. Presymptomatic genetic testing in children for neurofibromatosis 2. J Pediatr Nurs. 2008;23:183-94.
76. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31:1135-43.
77. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010;12:14-8.
78. Plotkin SR, Stemmer-Rachamimov AO, Barker 2nd FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358-67.
79. Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet. 1999;65:1342-8. (Pubitemid 30460384)
80. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-6. (Pubitemid 28325977)
81. Jagani Z, Mora-Blanco EL, Sansam CG, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010;16:1429-33.
82. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27:385-9.
83. Finkelstein-Shechter T, Gassas A, Mabbott D, et al. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol. 2010;32:e182-186.
84. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23:1491-9.
85. Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004;22:2877-84. (Pubitemid 41079907)
86. Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008;45:332-9. (Pubitemid 351839473)
87. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059-67. (Pubitemid 36695052)
88. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19:617-23.
89. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet. 2008;16:1289-300.
90. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13-27.
91. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11:687-94.
92. Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet. 1995;56:112-5.
93. Frappart PO, McKinnon PJ. Ataxia-telangiectasia and related diseases. Neuromolecular Med. 2006;8:495-511.
94. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep. 2004;5:772-6.
95. Mavrou A, Tsangaris GT, Roma E, Kolialexi A. The ATM gene and ataxia telangiectasia. Anticancer Res. 2008;28:401-5. (Pubitemid 351362844)